Y
Yoshikazu Inoue
Researcher at Cincinnati Children's Hospital Medical Center
Publications - 273
Citations - 17662
Yoshikazu Inoue is an academic researcher from Cincinnati Children's Hospital Medical Center. The author has contributed to research in topics: Idiopathic pulmonary fibrosis & Medicine. The author has an hindex of 48, co-authored 233 publications receiving 12648 citations. Previous affiliations of Yoshikazu Inoue include Niigata University.
Papers
More filters
Journal ArticleDOI
Successful Sirolimus Treatment of Lymphangioleiomyomatosis in a Hepatitis B Virus Carrier.
Shoko Sonobe,Toru Arai,Yasushi Tanimoto,Chikatoshi Sugimoto,Masanori Kitaichi,Masanori Akira,Takahiko Kasai,Masaki Hirose,Yoshikazu Inoue +8 more
TL;DR: Treatment with 1 mg daily of sirolimus was effective, as the chylous effusion resolved completely and the dyspnea improved, and the siro Limus dosage was increased to 2 mg daily without causing HBV reactivation.
Journal ArticleDOI
Predictive factors for relapse in corticosteroid-treated patients with chronic eosinophilic pneumonia
Naoko Takeuchi,Toru Arai,Yumiko Sasaki,Masanori Akira,Yoshinobu Matsuda,Kazunobu Tachibana,Takahiko Kasai,Yoshikazu Inoue +7 more
TL;DR: In this article, the authors investigated predictive factors for relapse in CS-treated cases of chronic eosinophilic pneumonia (CEP) and devised a relapse prediction model using two categorical parameters: the presence of centrilobular opacities and serum levels of SP-D (>135/≤135 ng/mL).
Journal ArticleDOI
Characteristics and prognosis of interstitial pneumonias complicated with pneumomediastinum.
Shojiro Minomo,Toru Arai,Hisao Higo,Taisuke Tsuji,Kazunobu Tachibana,Masanori Akira,Yoshikazu Inoue +6 more
TL;DR: Multivariate analysis revealed that IIPs and no improvement of pneumomediastinum were associated with poor prognosis, and patients with IIPs complicated with pneumophilia and those without improvement of lung function tests, treatments, and mortality hadpoor prognosis.
Journal ArticleDOI
Antimicrobial susceptibility patterns and MICs among non-photochromogenic rapidly growing Mycobacteroides and Mycolicibacterium species.
Shiomi Yoshida,Kazunari Tsuyuguchi,Kinuyo Chikamatsu,Akio Aono,Akiko Takaki,Satoshi Mitarai,Takehiko Kobayashi,Yoshikazu Inoue,Katsuhiro Suzuki +8 more
TL;DR: NPRGM clade-specific susceptibility patterns suggest an urgent need to establish distinct breakpoints for Myco and Mycolici species, both highly susceptible to amikacin and linezolid.
Journal ArticleDOI
The patient support program‘Educational Seminar for Sarcoidosis’held atthe 41st Annual Meeting of Japan Society of Sarcoidosis and Other Granulomatous Disorders
Hiromi Tomioka,Yoshikazu Inoue,Sonoko Nagai,Michiru Sawahata,Etsuro Yamaguchi,Fumio Terasaki,Kazuichi Maruyama,Kunio Hamada,Hiroshi Kuroda +8 more